

Cynthia Hawkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8434785/publications.pdf>

Version: 2024-02-01

252
papers

29,576
citations

32410

55
h-index

6177

164
g-index

266
all docs

266
docs citations

266
times ranked

29224
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. <i>Neuro-Oncology</i> , 2023, 25, 54-67.	0.6	5
2	Radiomic Features Based on MRI Predict Progression-Free Survival in Pediatric Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma. <i>Canadian Association of Radiologists Journal</i> , 2023, 74, 119-126.	1.1	6
3	A Practical Approach to the Evaluation and Diagnosis of Pediatric CNS Tumors. <i>Pediatric and Developmental Pathology</i> , 2022, 25, 6-9.	0.5	1
4	Characteristics of patients ≤ 10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	0.6	9
5	Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29316.	0.8	2
6	Childhood head trauma and the risk of childhood brain tumours: A case-control study in Ontario, Canada. <i>International Journal of Cancer</i> , 2022, 150, 795-801.	2.3	1
7	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. <i>Neuro-Oncology</i> , 2022, 24, 821-833.	0.6	9
8	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	15.2	53
9	OUP accepted manuscript. <i>American Journal of Clinical Pathology</i> , 2022, , .	0.4	2
10	Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma. <i>BMC Pediatrics</i> , 2022, 22, 13.	0.7	0
11	Splicing is an alternate oncogenic pathway activation mechanism in glioma. <i>Nature Communications</i> , 2022, 13, 588.	5.8	17
12	Ependymal Tumors. <i>Pediatric and Developmental Pathology</i> , 2022, 25, 59-67.	0.5	5
13	Medulloblastoma: WHO 2021 and Beyond. <i>Pediatric and Developmental Pathology</i> , 2022, 25, 23-33.	0.5	18
14	The diverse landscape of histone-mutant pediatric high-grade gliomas: A narrative review. <i>Glioma (Mumbai, India)</i> , 2022, 5, 5.	0.0	0
15	Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study. <i>JCO Precision Oncology</i> , 2022, 6, e2100286.	1.5	8
16	A novel central nervous system embryonal tumor successfully treated with multi-modal therapy highlights limitation of methylation-based tumor classification. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29520.	0.8	1
17	Building the ecosystem for pediatric neuro-oncology care in Pakistan: Results of a 7-year long twinning program between Canada and Pakistan. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29726.	0.8	4
18	Recurrent ACVR1 mutations in posterior fossa ependymoma. <i>Acta Neuropathologica</i> , 2022, 144, 373-376.	3.9	7

#	ARTICLE	IF	CITATIONS
19	Liquid biopsy for pediatric brain tumor patients: is it prime time yet?. <i>Neuro-Oncology</i> , 2022, 24, 1773-1775.	0.6	1
20	IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study. <i>Neuro-Oncology</i> , 2022, 24, i84-i84.	0.6	1
21	IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors. <i>Neuro-Oncology</i> , 2022, 24, i85-i85.	0.6	2
22	LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults. <i>Neuro-Oncology</i> , 2022, 24, i97-i97.	0.6	0
23	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. <i>Neuro-Oncology</i> , 2022, 24, i61-i62.	0.6	0
24	Abstract 5224: The PRrecision Oncology For Young peopLE (PROFYLE) Program: A national precision oncology program for children, adolescents and young adults with hard-to-cure cancer in Canada. <i>Cancer Research</i> , 2022, 82, 5224-5224.	0.4	1
25	Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression. <i>Communications Biology</i> , 2022, 5, .	2.0	8
26	Giant choroid plexus cysts with calvarial erosion: a case report and literature review. <i>Child's Nervous System</i> , 2021, 37, 2381-2385.	0.6	2
27	Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28561.	0.8	2
28	Re-irradiation with concurrent BRAF and MEK inhibitor therapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28838.	0.8	2
29	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	3.9	44
30	Longitudinal Assessment of Enhancing Foci of Abnormal Signal Intensity in Neurofibromatosis Type 1. <i>American Journal of Neuroradiology</i> , 2021, 42, 766-773.	1.2	1
31	Radiomics of Pediatric Low-Grade Gliomas: Toward a Pretherapeutic Differentiation of BRAF-Mutated and BRAF-Fused Tumors. <i>American Journal of Neuroradiology</i> , 2021, 42, 759-765.	1.2	32
32	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	0.8	40
33	Abstract PO052: Uncovering the evolution of Glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers. , 2021, , .		0
34	Pediatric Glial Tumors. <i>Pediatric and Developmental Pathology</i> , 2021, , 109352662110091.	0.5	3
35	MetaFusion: a high-confidence metacaller for filtering and prioritizing RNA-seq gene fusion candidates. <i>Bioinformatics</i> , 2021, 37, 3144-3151.	1.8	6
36	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021, 23, 1231-1251.	0.6	4,534

#	ARTICLE	IF	CITATIONS
37	HGG-39. ALTERNATIVE SPLICING OF NEUROFIBROMIN 1 IS ASSOCIATED WITH ELEVATED MAPK ACTIVITY AND POOR PROGNOSIS IN HIGH-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, i25-i25.	0.6	0
38	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611.	0.6	22
39	OMRT-8. Precision targeting of cellular pathways with complementary diagnostics. <i>Neuro-Oncology Advances</i> , 2021, 3, ii8-ii8.	0.4	0
40	Abstract 636: PROFYLE: The pan-Canadian precision oncology program for children, adolescents and young adults with hard-to-treat cancer. , 2021, , .		3
41	Local FK506 drug delivery enhances nerve regeneration through fresh, unprocessed peripheral nerve allografts. <i>Experimental Neurology</i> , 2021, 341, 113680.	2.0	23
42	Upfront Adjuvant Immunotherapy of Replication Repairâ€“Deficient Pediatric Glioblastoma With Chemoradiation-Sparing Approach. <i>JCO Precision Oncology</i> , 2021, 5, 1426-1431.	1.5	6
43	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	0.8	40
44	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 800-813.	2.7	12
45	SYST-04. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. <i>Neuro-Oncology Advances</i> , 2021, 3, iv9-iv9.	0.4	2
46	EXTH-30. HARNESSING CELLULAR STRESS FOR IMMUNE TARGETING OF DIPGS. <i>Neuro-Oncology</i> , 2021, 23, vi169-vi170.	0.6	0
47	CTNI-06. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi60.	0.6	1
48	INNV-43. MORE THAN WHAT MEETS THE EYE: ETMR AN UNDER RECOGNISED ATYPICAL BRAINSTEM PRIMARY. A RARE BRAIN TUMOR CONSORTIUM (RBTC) STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi114-vi115.	0.6	0
49	Germline predisposition to glial neoplasms in children and young adults: A narrative review. <i>Glioma (Mumbai, India)</i> , 2021, 4, 68.	0.0	1
50	Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 814228.	1.3	7
51	EPCO-16. ONCOHISTONE INTERACTOME PROFILING UNCOVERS MECHANISMS OF CHROMATIN DISRUPTION AND IDENTIFIES POTENTIAL THERAPEUTIC TARGETS IN PEDIATRIC HIGH-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi5-vi5.	0.6	0
52	BRAF V600E mutant oligodendrogliomaâ€“like tumors with chromosomal instability in adolescents and young adults. <i>Brain Pathology</i> , 2020, 30, 515-523.	2.1	8
53	Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 139-151.	0.6	49
54	Multiplexed Digital Detection of B-Cell Acute Lymphoblastic Leukemia Fusion Transcripts Using the NanoString nCounter System. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 72-80.	1.2	10

#	ARTICLE	IF	CITATIONS
55	Modeling DIPG in the mouse brainstem. <i>Neuro-Oncology</i> , 2020, 22, 307-308.	0.6	1
56	B7 ^h as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors. <i>Translational Oncology</i> , 2020, 13, 365-371.	1.7	33
57	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241.	3.9	65
58	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). <i>Journal of Clinical Oncology</i> , 2020, 38, 223-231.	0.8	40
59	Indolent course of brainstem tumors with K27M ^{H3.3} mutation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28102.	0.8	4
60	Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa103.	0.4	6
61	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. <i>Cell Reports</i> , 2020, 33, 108286.	2.9	39
62	An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. <i>Nature Communications</i> , 2020, 11, 3627.	5.8	21
63	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). <i>Journal of Neuro-Oncology</i> , 2020, 149, 45-54.	1.4	8
64	Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer. <i>Nature Communications</i> , 2020, 11, 6216.	5.8	35
65	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. <i>Acta Neuropathologica</i> , 2020, 140, 765-776.	3.9	23
66	Cancer proteome and metabolite changes linked to SHMT2. <i>PLoS ONE</i> , 2020, 15, e0237981.	1.1	18
67	Diffuse midline glioma: review of epigenetics. <i>Journal of Neuro-Oncology</i> , 2020, 150, 27-34.	1.4	29
68	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii328.	0.6	0
69	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. <i>JCO Precision Oncology</i> , 2020, 4, 561-571.	1.5	62
70	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. <i>Neuro-Oncology</i> , 2020, 22, 1647-1657.	0.6	51
71	cIMPACT ^{NOW} update 7: advancing the molecular classification of ependymal tumors. <i>Brain Pathology</i> , 2020, 30, 863-866.	2.1	168
72	Pediatric low-grade glioma in the era of molecular diagnostics. <i>Acta Neuropathologica Communications</i> , 2020, 8, 30.	2.4	172

#	ARTICLE	IF	CITATIONS
73	Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas. <i>Cancer Cell</i> , 2020, 37, 308-323.e12.	7.7	56
74	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784.	0.6	44
75	Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 437-447.	0.9	19
76	An update on the CNS manifestations of brain tumor polyposis syndromes. <i>Acta Neuropathologica</i> , 2020, 139, 703-715.	3.9	33
77	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. <i>Cancer Cell</i> , 2020, 37, 569-583.e5.	7.7	244
78	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1474-1483.	0.6	39
79	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. <i>Nature Medicine</i> , 2020, 26, 720-731.	15.2	141
80	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	2.1	363
81	Pearls & Oy-sters: Fatal brain edema is a rare complication of severe CACNA1A-related disorder. <i>Neurology</i> , 2020, 94, 631-634.	1.5	7
82	Medulloblastoma Arises from the Persistence of a Rare and Transient Sox2+ Granule Neuron Precursor. <i>Cell Reports</i> , 2020, 31, 107511.	2.9	35
83	IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii363-iii363.	0.6	1
84	MBRS-54. POOR SURVIVAL IN REPLICATION REPAIR DEFICIENT HYPERMUTANT MEDULLOBLASTOMA AND CNS EMBRYONAL TUMORS: A REPORT FROM THE INTERNATIONAL RRD CONSORTIUM. <i>Neuro-Oncology</i> , 2020, 22, iii407-iii407.	0.6	1
85	ATRT-33. ENABLING RAPID CLASSIFICATION OF ATRT WITH NANOSTRING NCOUNTER PLATFORM. <i>Neuro-Oncology</i> , 2020, 22, iii282-iii282.	0.6	0
86	MBCL-25. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES. <i>Neuro-Oncology</i> , 2020, 22, iii393-iii394.	0.6	3
87	MODL-25. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS, MECHANISMS OF IMMUNE EVASION, AND COMBINATORIAL IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii416-iii416.	0.6	0
88	DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. <i>Neuro-Oncology</i> , 2020, 22, iii295-iii296.	0.6	0
89	LGG-13. THE CLINICAL AND MOLECULAR LANDSCAPE OF GLIOMAS IN ADOLESCENTS AND YOUNG ADULTS. <i>Neuro-Oncology</i> , 2020, 22, iii368-iii368.	0.6	0
90	LGG-19. SPINAL LOW-GRADE GLIOMAS IN CANADIAN CHILDREN: A MULTI-CENTRE RETROSPECTIVE REVIEW. <i>Neuro-Oncology</i> , 2020, 22, iii369-iii370.	0.6	0

#	ARTICLE	IF	CITATIONS
91	ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii327.	0.6	0
92	LGG-34. CLINICAL AND MOLECULAR CHARACTERIZATION OF A MULTI-INSTITUTIONAL COHORT OF PEDIATRIC SPINAL CORD LOW-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii373-iii373.	0.6	0
93	HGG-20. DIAGNOSTIC AND BIOLOGICAL ROLE OF METHYLATION PATTERNS IN REPLICATION REPAIR DEFICIENT HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii347-iii348.	0.6	0
94	LGG-50. INTEGRATED MOLECULAR AND CLINICAL ANALYSIS OF 1,000 PEDIATRIC LOW-GRADE GLIOMAS UNCOVERS NOVEL SUBGROUPS FOR CLINICAL RISK STRATIFICATION. <i>Neuro-Oncology</i> , 2020, 22, iii375-iii376.	0.6	0
95	DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. <i>Neuro-Oncology</i> , 2020, 22, iii298-iii299.	0.6	0
96	PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii427-iii427.	0.6	0
97	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. <i>Neuro-Oncology</i> , 2020, 22, iii371-iii371.	0.6	1
98	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. <i>Neuro-Oncology</i> , 2020, 22, iii377-iii377.	0.6	0
99	TAMI-29. MULTIFACTORIAL UPREGULATION OF ID1 DRIVES DIPG INVASIVENESS AND IS THERAPEUTICALLY TARGETABLE. <i>Neuro-Oncology</i> , 2020, 22, ii219-ii219.	0.6	0
100	NIMG-31. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. <i>Neuro-Oncology</i> , 2020, 22, ii154-ii154.	0.6	0
101	CTNI-24. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. <i>Neuro-Oncology</i> , 2020, 22, ii47-ii47.	0.6	0
102	DDRE-06. CELLULAR STRESS RESPONSE IN DIPG THERAPY. <i>Neuro-Oncology</i> , 2020, 22, ii62-ii62.	0.6	0
103	Sarcoma Subgrouping by Detection of Fusion Transcripts Using NanoString nCounter Technology. <i>Pediatric and Developmental Pathology</i> , 2019, 22, 205-213.	0.5	11
104	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. <i>Clinical Epigenetics</i> , 2019, 11, 117.	1.8	21
105	MEDU-04. AN OTX2-PAX GENE NETWORK REGULATES GROUP 3 MEDULLOBLASTOMA DIFFERENTIATION AND TUMOR GROWTH. <i>Neuro-Oncology</i> , 2019, 21, ii103-ii104.	0.6	0
106	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. <i>Journal of Neuro-Oncology</i> , 2019, 145, 107-114.	1.4	18
107	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	5.8	200
108	Transcriptional repressor REST drives lineage stage-specific chromatin compaction at <i>Ptch1</i> and increases AKT activation in a mouse model of medulloblastoma. <i>Science Signaling</i> , 2019, 12, .	1.6	19

#	ARTICLE	IF	CITATIONS
109	Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review. <i>Child's Nervous System</i> , 2019, 35, 861-864.	0.6	9
110	Repeat irradiation for children with supratentorial high-grade glioma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27881.	0.8	14
111	Ongoing issues with the management of children with Constitutional Mismatch Repair Deficiency syndrome. <i>European Journal of Medical Genetics</i> , 2019, 62, 103706.	0.7	7
112	DIPG-22. GENETIC MODELING IMPLICATES RAS AND MYC AS KEY EPIGENETICALLY ACTIVATED TRANSCRIPTIONAL TARGETS OF H3K27M-DRIVEN CANCER. <i>Neuro-Oncology</i> , 2019, 21, ii73-ii73.	0.6	0
113	DIPG-35. OPEN DIPG INITIATIVE: A PLATFORM FOR ACCELERATING DISCOVERY THROUGH DATA ACCESS, CONSOLIDATION AND HARMONIZATION. <i>Neuro-Oncology</i> , 2019, 21, ii76-ii76.	0.6	0
114	HGG-22. CHARACTERIZING THE ROLE H3.3G34R MUTATION IN PEDIATRIC HIGH GRADE ASTROCYTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii91-ii91.	0.6	0
115	LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FROM THE INTERNATIONAL PLGG TASKFORCE. <i>Neuro-Oncology</i> , 2019, 21, ii100-ii100.	0.6	0
116	DIPG-36. CLINICAL, RADIOLOGICAL, AND HISTO-MOLECULAR CHARACTERISTICS OF DIFFUSE INTRINSIC PONTINE GLIOMA IN PATIENTS WHO SURVIVE LESS THAN 3 MONTHS FROM DIAGNOSIS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2019, 21, ii76-ii77.	0.6	0
117	IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. <i>Neuro-Oncology</i> , 2019, 21, ii96-ii97.	0.6	0
118	LGG-01. BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENT AND YOUNG ADULT. <i>Neuro-Oncology</i> , 2019, 21, ii98-ii98.	0.6	0
119	HGG-18. ALTERNATIVE SPLICING OF NEUROFIBROMIN 1 IS ASSOCIATED WITH ELEVATED MAPK ACTIVITY AND POOR PROGNOSIS IN HIGH-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, ii90-ii90.	0.6	0
120	HGG-19. MOLECULAR ANALYSIS UNCOVERS 3 DISTINCT SUBGROUPS AND MULTIPLE TARGETABLE GENE FUSIONS IN INFANT GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, ii90-ii91.	0.6	0
121	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. <i>Acta Neuropathologica</i> , 2019, 137, 683-687.	3.9	170
122	Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. <i>Nature Communications</i> , 2019, 10, 797.	5.8	24
123	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. <i>Cancer</i> , 2019, 125, 1867-1876.	2.0	49
124	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. <i>Neuro-Oncology</i> , 2019, 21, ii102-ii102.	0.6	0
125	MEDU-34. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii110-ii110.	0.6	10
126	Acute MR-Guided High-Intensity Focused Ultrasound Lesion Assessment Using Diffusion-Weighted Imaging and Histological Analysis. <i>Frontiers in Neurology</i> , 2019, 10, 1069.	1.1	10

#	ARTICLE	IF	CITATIONS
127	TMOD-10. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS AND COMBINATIONAL IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2019, 21, ii123-ii123.	0.6	0
128	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 253-263.	1.4	30
129	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 547-557.	0.6	32
130	Detecting Stem Cell Marker Expression Using the NanoString nCounter System. <i>Methods in Molecular Biology</i> , 2019, 1869, 57-67.	0.4	2
131	Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis. <i>Frontiers in Immunology</i> , 2019, 10, 3045.	2.2	4
132	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26988.	0.8	51
133	Mitochondrial POLG related disorder presenting prenatally with fetal cerebellar growth arrest. <i>Metabolic Brain Disease</i> , 2018, 33, 1369-1373.	1.4	7
134	Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 478-482.	0.3	17
135	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018, 20, 160-173.	0.6	116
136	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	0.8	250
137	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, i106-i106.	0.6	0
138	ATRT-40. IMPACT OF MOLECULAR SUBTYPES ON TREATMENT OUTCOMES IN RHABDOID TUMORS - A REPORT FROM THE RARE TUMOR CONSORTIUM. <i>Neuro-Oncology</i> , 2018, 20, i36-i36.	0.6	0
139	DIPG-55. TARGETING SENESCENT CELLS WITH ABT-263 ENHANCES CELL DEATH INDUCED BY BMI1 INHIBITION AND IONIZING RADIATION IN DIPG. <i>Neuro-Oncology</i> , 2018, 20, i60-i60.	0.6	0
140	EPEN-31. SUBGROUP SPECIFIC LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOMES IN POSTERIOR FOSSA EPENDYMOMA (PFE). <i>Neuro-Oncology</i> , 2018, 20, i79-i79.	0.6	0
141	HGG-17. TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , 2018, 20, i92-i92.	0.6	0
142	MBCL-08. MOLECULAR CHARACTERIZATION OF NODULAR DESMOPLASTIC MEDULLOBLASTOMAS IN YOUNG CHILDREN TREATED ON ACNS1221. A REPORT FROM THE CHILDREN ONCOLOGY GROUP. <i>Neuro-Oncology</i> , 2018, 20, i118-i119.	0.6	2
143	MBRS-62. REPRESSIVE CHROMATIN REMODELERS IN SHH-DRIVEN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i141-i141.	0.6	0
144	IMMU-25. PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) IS NOT EXPRESSED IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) TUMOR CELLS. <i>Neuro-Oncology</i> , 2018, 20, vi126-vi126.	0.6	2

#	ARTICLE	IF	CITATIONS
145	EAPH-06. HYPERMUTANT PEDIATRIC HIGH GRADE GLIOMAS ARE DRIVEN BY RAS/MAPK MUTATIONS AND RESPOND TO MEK INHIBITION. <i>Neuro-Oncology</i> , 2018, 20, i66-i66.	0.6	0
146	LGG-60. THE GENETIC LANDSCAPE OF PEDIATRIC LOW-GRADE GLIOMAS: INCIDENCE, PROGNOSIS AND RESPONSE TO THERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	0.6	1
147	TBIO-30. MOLECULAR LANDSCAPE AND CLINICAL CORRELATIONS OF CNS SARCOMAS. <i>Neuro-Oncology</i> , 2018, 20, i186-i186.	0.6	0
148	LGG-49. MOLECULAR ALTERATIONS IN PREGNANT ADOLESCENT AND YOUNG ADULT WOMEN WITH GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, i115-i115.	0.6	0
149	DIPG-69. CHARACTERISTICS OF PATIENTS \geq 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	0.6	1
150	EMBR-12. IMPROVED DIAGNOSTIC ALGORITHM FOR DIFFERENTIAL DIAGNOSTICS OF CNS EMBRYONAL TUMORS (FORMER CNS-PNET) BY NEUROPATHOLOGICAL RE-EVALUATION OF 256 CASES AND CROSSVALIDATION BY METHYLATION CLASSIFICATION. <i>Neuro-Oncology</i> , 2018, 20, i71-i71.	0.6	0
151	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	0.6	0
152	Two different STAT1 gain-of-function mutations lead to diverse IFN- β -mediated gene expression. <i>Npj Genomic Medicine</i> , 2018, 3, 23.	1.7	14
153	DIPG-38. ID1 EXPRESSION CORRELATES WITH H3F3A K27M MUTATION AND EXTRA-PONTINE INVASION IN DIPG. <i>Neuro-Oncology</i> , 2018, 20, i56-i56.	0.6	0
154	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. <i>Neuro-Oncology</i> , 2018, 20, i72-i73.	0.6	0
155	CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. <i>Cancer Research</i> , 2018, 78, 4745-4759.	0.4	31
156	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. <i>Neuro-Oncology</i> , 2018, 20, i72-i72.	0.6	4
157	DIPG-70. CLINICAL, RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN $<$ 3 YEARS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	0.6	0
158	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	0.6	73
159	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017, 19, now101.	0.6	217
160	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. <i>Journal of Neuro-Oncology</i> , 2017, 132, 155-162.	1.4	43
161	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 323-331.	1.4	27
162	Prognostic relevance of miR-124-3p and its target <i>TP53INP1</i> in pediatric ependymoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 639-650.	1.5	16

#	ARTICLE	IF	CITATIONS
163	H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. <i>Child's Nervous System</i> , 2017, 33, 1047-1051.	0.6	46
164	A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment. <i>Brain Tumor Pathology</i> , 2017, 34, 51-61.	1.1	46
165	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. <i>Acta Neuropathologica</i> , 2017, 133, 1-3.	3.9	120
166	Noncompaction cardiomyopathy in an infant with Walker's Warburg syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 3082-3086.	0.7	8
167	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. <i>Cancer Cell</i> , 2017, 32, 520-537.e5.	7.7	716
168	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	13.5	596
169	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. <i>Acta Neuropathologica</i> , 2017, 134, 705-714.	3.9	168
170	Identification of complex genomic rearrangements in cancers using CouGaR. <i>Genome Research</i> , 2017, 27, 107-117.	2.4	31
171	cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 27, 851-852.	2.1	63
172	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. <i>Brain Pathology</i> , 2017, 27, 411-418.	2.1	58
173	Embryonal tumor with multilayered rosettes, C19MC-altered: Report of an extremely rare malignant pediatric central nervous system neoplasm. <i>SAGE Open Medical Case Reports</i> , 2017, 5, 2050313X1774520.	0.2	8
174	Germline and somatic mutations in <i>STXBP1</i> with diverse neurodevelopmental phenotypes. <i>Neurology: Genetics</i> , 2017, 3, e199.	0.9	41
175	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	0.8	232
176	ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age: A report from the Children Oncology Group.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10505-10505.	0.8	7
177	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10503-10503.	0.8	0
178	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. <i>Neuro-Oncology</i> , 2016, 18, iii94.1-iii94.	0.6	0
179	PNR-32UPDATE OF DIAGNOSTICS OF PRIMITIVE NEUROECTODERMAL TUMOURS OF THE CNS - NEUROPATHOLOGICAL RE-EVALUATION OF 99 CASES. <i>Neuro-Oncology</i> , 2016, 18, iii13.1-iii13.	0.6	0
180	High frequency of mismatch repair deficiency among pediatric high grade gliomas in <sc>ordan. <i>International Journal of Cancer</i> , 2016, 138, 380-385.	2.3	62

#	ARTICLE	IF	CITATIONS
181	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update. <i>Child's Nervous System</i> , 2016, 32, 1789-1797.	0.6	26
182	Management and outcome of chordomas in the pediatric population: The Hospital for Sick Children experience and review of the literature. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 169-176.	0.8	29
183	Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. <i>Acta Neuropathologica Communications</i> , 2016, 4, 93.	2.4	100
184	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4161-4170.	0.8	72
185	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. <i>Science Translational Medicine</i> , 2016, 8, 366ra161.	5.8	144
186	Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2038-2041.	0.8	57
187	LG-19IMMUNOHISTOCHEMISTRY IS HIGHLY SENSITIVE AND SPECIFIC FOR THE DETECTION OF BRAF V600E STATUS IN PEDIATRIC LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2016, 18, iii82.3-iii82.	0.6	1
188	PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. <i>Cancer Research</i> , 2016, 76, 4708-4719.	0.4	107
189	Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. <i>Cancer</i> , 2016, 122, 1261-1269.	2.0	109
190	Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. <i>Neuro-Oncology</i> , 2016, 18, 291-297.	0.6	112
191	Rasmussen's encephalitis: advances in management and patient outcomes. <i>Child's Nervous System</i> , 2016, 32, 629-640.	0.6	27
192	Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. <i>Acta Neuropathologica Communications</i> , 2016, 4, 1.	2.4	144
193	Pediatric thalamic tumors in the MRI era: a Canadian perspective. <i>Child's Nervous System</i> , 2016, 32, 269-280.	0.6	37
194	JPO2/CDCA7L and LEDGF/p75 Are Novel Mediators of PI3K/AKT Signaling and Aggressive Phenotypes in Medulloblastoma. <i>Cancer Research</i> , 2016, 76, 2802-2812.	0.4	18
195	Lethal Disorder of Mitochondrial Fission Caused by Mutations in DNM1L. <i>Journal of Pediatrics</i> , 2016, 171, 313-316.e2.	0.9	67
196	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. <i>Nature Genetics</i> , 2016, 48, 273-282.	9.4	214
197	Hemorrhagic presentations of cerebellar pilocytic astrocytomas in children resulting in death: report of 2 cases. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 17, 446-452.	0.8	15
198	Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation. <i>Child's Nervous System</i> , 2016, 32, 553-557.	0.6	13

#	ARTICLE	IF	CITATIONS
199	Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.. Journal of Clinical Oncology, 2016, 34, 10509-10509.	0.8	3
200	Re-irradiation for relapsed paediatric ependymoma.. Journal of Clinical Oncology, 2016, 34, 10565-10565.	0.8	1
201	Imaging of metastatic medulloblastoma in the molecular era.. Journal of Clinical Oncology, 2016, 34, e22003-e22003.	0.8	0
202	Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. Frontiers in Oncology, 2015, 5, 147.	1.3	91
203	Massive CAG Repeat Expansion and Somatic Instability in Maternally Transmitted Infantile Spinocerebellar Ataxia Type 7. JAMA Neurology, 2015, 72, 219.	4.5	22
204	Study of the biodistribution of fluorescein in glioma-infiltrated mouse brain and histopathological correlation of intraoperative findings in high-grade gliomas resected under fluorescein fluorescence guidance. Journal of Neurosurgery, 2015, 122, 1360-1369.	0.9	166
205	BT-02 * FUNCTIONALLY-DEFINED THERAPEUTIC TARGETS IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2015, 17, iii3-iii3.	0.6	2
206	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermuted cancers. Nature Genetics, 2015, 47, 257-262.	9.4	306
207	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	3.2	84
208	Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. European Journal of Cancer, 2015, 51, 977-983.	1.3	87
209	A preclinical study demonstrating the efficacy of nilotinib in inhibiting the growth of pediatric high-grade glioma. Journal of Neuro-Oncology, 2015, 122, 471-480.	1.4	6
210	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	15.2	473
211	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clinical Cancer Research, 2015, 21, 3750-3758.	3.2	40
212	Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. Molecular Cancer Therapeutics, 2015, 14, 2560-2568.	1.9	55
213	Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. Pediatric Neurology, 2015, 53, 238-242.e1.	1.0	6
214	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.. Journal of Clinical Oncology, 2015, 33, 2019-2019.	0.8	1
215	A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. Oncotarget, 2015, 6, 2709-2724.	0.8	24
216	Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta Neuropathologica, 2014, 128, 863-877.	3.9	34

#	ARTICLE	IF	CITATIONS
217	Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. <i>Acta Neuropathologica</i> , 2014, 128, 573-581.	3.9	258
218	ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents. <i>Cancer Discovery</i> , 2014, 4, 1198-1213.	7.7	55
219	Developmental stage-specific transformation of neural progenitors. <i>Cell Cycle</i> , 2014, 13, 343-344.	1.3	0
220	Genetic alterations in paediatric high grade astrocytomas. <i>Diagnostic Histopathology</i> , 2014, 20, 84-90.	0.2	1
221	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. <i>Nature Genetics</i> , 2014, 46, 451-456.	9.4	525
222	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. <i>Nature Reviews Cancer</i> , 2014, 14, 92-107.	12.8	469
223	DETAILED MOLECULAR CHARACTERISATION OF DIFFUSE INTRINSIC PONTINE GLIOMAS IDENTIFIES THREE MOLECULAR SUBGROUPS AND A NOVEL CANCER DRIVER, ACVR1. <i>Neuro-Oncology</i> , 2014, 16, iii26-iii27.	0.6	0
224	International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumour Classification and Grading. <i>Brain Pathology</i> , 2014, 24, 429-435.	2.1	499
225	Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. <i>European Journal of Cancer</i> , 2014, 50, 987-996.	1.3	180
226	Loss of p53 cooperates with Kras activation to induce glioma formation in a region-independent manner. <i>Glia</i> , 2013, 61, 1862-1872.	2.5	19
227	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	5.1	307
228	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. <i>Lancet Oncology</i> , The, 2013, 14, 534-542.	5.1	212
229	Differential transformation capacity of neuro-glial progenitors during development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 14378-14383.	3.3	13
230	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor <i>MYBL1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8188-8193.	3.3	188
231	Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10029-10029.	0.8	2
232	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. <i>Acta Neuropathologica</i> , 2012, 124, 439-447.	3.9	799
233	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. <i>Cell</i> , 2012, 148, 59-71.	13.5	743
234	Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1358-1363.	0.8	198

#	ARTICLE	IF	CITATIONS
235	Alkylpurineâ€œDNAâ€œN-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. <i>Journal of Clinical Investigation</i> , 2012, 122, 253-266.	3.9	140
236	<i>BRAF-KIAA1549</i> Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma. <i>Clinical Cancer Research</i> , 2011, 17, 4790-4798.	3.2	219
237	GLI2 Is a Potential Therapeutic Target in Pediatric Medulloblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 430-437.	0.9	20
238	Cribriform neuroepithelial tumour: novel clinicopathological, ultrastructural and cytogenetic findings. <i>Acta Neuropathologica</i> , 2011, 122, 511-514.	3.9	24
239	Reply to J.C. Lindsey et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e347-e347.	0.8	2
240	Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas. <i>Clinical Cancer Research</i> , 2011, 17, 4650-4660.	3.2	135
241	A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. <i>Journal of Experimental Medicine</i> , 2011, 208, 689-702.	4.2	77
242	Viruses and human brain tumors: cytomegalovirus enters the fray. <i>Journal of Clinical Investigation</i> , 2011, 121, 3831-3833.	3.9	13
243	TP53 Alterations Determine Clinical Subgroups and Survival of Patients With Choroid Plexus Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 1995-2001.	0.8	189
244	Whole-Genome Profiling of Pediatric Diffuse Intrinsic Pontine Gliomas Highlights Platelet-Derived Growth Factor Receptor β and Poly (ADP-ribose) Polymerase As Potential Therapeutic Targets. <i>Journal of Clinical Oncology</i> , 2010, 28, 1337-1344.	0.8	292
245	A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. <i>European Journal of Cancer</i> , 2009, 45, 2352-2359.	1.3	34
246	Tyrosine kinase expression in pediatric high grade astrocytoma. <i>Journal of Neuro-Oncology</i> , 2008, 87, 247-253.	1.4	51
247	The Role of Telomere Maintenance in the Spontaneous Growth Arrest of Pediatric Low-Grade Gliomas. <i>Neoplasia</i> , 2006, 8, 136-142.	2.3	72
248	The neuroprotective effects of anti-cd18 therapy after transient global ischemic brain injury in the mouse. <i>Canadian Journal of Anaesthesia</i> , 2006, 53, 26428-26428.	0.7	0
249	Human Telomere Reverse Transcriptase Expression Predicts Progression and Survival in Pediatric Intracranial Ependymoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1522-1528.	0.8	106
250	Identification of human brain tumour initiating cells. <i>Nature</i> , 2004, 432, 396-401.	13.7	6,758
251	Identification of a cancer stem cell in human brain tumors. <i>Cancer Research</i> , 2003, 63, 5821-8.	0.4	3,675
252	Clinical Neuropathological Conference: Thereâ€™s a Child in All of Us. <i>Canadian Journal of Neurological Sciences</i> , 0, , 1-5.	0.3	0